Pharmalittle: Mylan uses coal to get tax breaks; FDA to speed orphan drug designations
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far and remember there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup of stimulation. Our flavor today is Mocha Nut Fudge. And remember: No prescription is required. Meanwhile, here is the latest menu of tidbits to help you on your way. Have a wonderful day and please do stay in touch …
Since 2011, Mylan has lowered its tax bill by buying 99 percent stakes in five companies in the U.S. that own plants that process coal to reduce smog-causing emissions, Reuters reports. The drug maker then sells the coal at a loss to power plants that generated hundreds of millions of dollars in tax credits over the last six years. The coal credits were approved by Congress in 2004 to provide incentives to fund production of cleaner coal, and expire after 2021.
